GlassScriptPhysician profile
Anne R Gonzalez
NPI 1821030834
$1,424.47
in general payments reported to CMS, 2019-2025
31 companies · $14.88 in 2025
The $14.88 reported for 2025 was less than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $473 · 2020: $251 · 2021: $355 · 2022: $114 · 2023: $186 · 2024: $31.30 · 2025: $14.88.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $232.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $231.71 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $294.17 | 2019-2022 | |
| Lupin INC. | $124.85 | 2019-2020 | |
| Currax Pharmaceuticals LLC | $99.58 | 2021-2022 | |
| Merz North America, INC. | $98.09 | 2023 | |
| Lilly USA, LLC | $87.12 | 2019-2024 | Jardiance, Zepbound |
| Allergan, INC. | $81.95 | 2019-2020 | |
| Daiichi Sankyo INC. | $77.76 | 2020 | |
| Abbvie INC. | $68.47 | 2021-2024 | |
| Pfizer INC. | $67.86 | 2023 | |
| Biohaven Pharmaceuticals, INC. | $42.05 | 2020-2021 | |
| Astrazeneca Pharmaceuticals LP | $38.08 | 2019-2021 | |
| Sanofi-Aventis U.S. LLC | $29.77 | 2019-2021 | |
| Exeltis, USA INC. | $29.65 | 2019-2020 | |
| Astellas Pharma US INC | $29.07 | 2021 | |
| Mylan Pharmaceuticals INC. | $22.95 | 2020 |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biohaven Pharmaceutical Holding Company LTD. | $20.84 | 2022 | |
| Glaxosmithkline, LLC. | $19.87 | 2020 | |
| Pacira Pharmaceuticals Incorporated | $16.80 | 2021 | |
| Abbott Laboratories | $16.08 | 2022 | |
| Amgen INC. | $16.01 | 2019 | |
| Therapeuticsmd, INC. | $15.20 | 2021 | |
| Ascensia Diabetes Care US INC. | $14.88 | 2025 | |
| Amarin Pharma, INC. | $14.85 | 2021 | |
| Agile Therapeutics, INC. | $13.68 | 2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $13.45 | 2020 | |
| Bausch Health US, LLC | $13.44 | 2021 | |
| Janssen Pharmaceuticals, INC | $12.20 | 2021 | |
| Avion Pharmaceuticals | $11.65 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $11.61 | 2021 | |
| Forte Bio-Pharma LLC | $11.59 | 2019 | |
| Teva Pharmaceuticals USA, INC. | $10.90 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Anne Gonzalez listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.